274 related articles for article (PubMed ID: 16698948)
1. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.
Tse GM; Tan PH; Lui PC; Gilks CB; Poon CS; Ma TK; Law BK; Lam WW
J Clin Pathol; 2007 Mar; 60(3):315-20. PubMed ID: 16698948
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathologic and immunohistochemical study of 187 cases of intraductal papillary neoplasm of breast].
Zhang H; Xiong Y; Zhang S; Zhang Y; Wang YH; Li T
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):726-31. PubMed ID: 22336153
[TBL] [Abstract][Full Text] [Related]
3. Myoepithelial cells in solid variant of intraductal papillary carcinoma of the breast: a potential diagnostic pitfall and a proposal of an immunohistochemical panel in the differential diagnosis with intraductal papilloma with usual ductal hyperplasia.
Moritani S; Ichihara S; Kushima R; Okabe H; Bamba M; Kobayashi TK; Hattori T
Virchows Arch; 2007 May; 450(5):539-47. PubMed ID: 17377808
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ?
Tan PH; Aw MY; Yip G; Bay BH; Sii LH; Murugaya S; Tse GM
Am J Surg Pathol; 2005 May; 29(5):625-32. PubMed ID: 15832086
[TBL] [Abstract][Full Text] [Related]
5. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast.
Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T
Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical staining of papillary breast lesions.
Troxell ML; Masek M; Sibley RK
Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):145-53. PubMed ID: 17525625
[TBL] [Abstract][Full Text] [Related]
7. Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas.
Hill CB; Yeh IT
Am J Clin Pathol; 2005 Jan; 123(1):36-44. PubMed ID: 15762278
[TBL] [Abstract][Full Text] [Related]
8. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers.
Collins LC; Carlo VP; Hwang H; Barry TS; Gown AM; Schnitt SJ
Am J Surg Pathol; 2006 Aug; 30(8):1002-7. PubMed ID: 16861972
[TBL] [Abstract][Full Text] [Related]
9. p63 expression in benign and malignant breast lesions.
Stefanou D; Batistatou A; Nonni A; Arkoumani E; Agnantis NJ
Histol Histopathol; 2004 Apr; 19(2):465-71. PubMed ID: 15024707
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
Popnikolov NK; Cavone SM; Schultz PM; Garcia FU
Mod Pathol; 2005 Dec; 18(12):1535-41. PubMed ID: 16258511
[TBL] [Abstract][Full Text] [Related]
11. Papillary neoplasia of the breast: immunohistochemically defined myoepithelial cells in the diagnosis of benign and malignant papillary breast neoplasms.
Raju UB; Lee MW; Zarbo RJ; Crissman JD
Mod Pathol; 1989 Nov; 2(6):569-76. PubMed ID: 2479944
[TBL] [Abstract][Full Text] [Related]
12. Use of p63 and CD10 in the differential diagnosis of papillary neoplasms of the breast.
de Moraes Schenka NG; Schenka AA; de Souza Queiroz L; de Almeida Matsura M; Vassallo J; Alvarenga M
Breast J; 2008; 14(1):68-75. PubMed ID: 18086274
[TBL] [Abstract][Full Text] [Related]
13. Pathology of breast papillary neoplasms: Community hospital experience.
Vdovenko AA
Ann Diagn Pathol; 2020 Dec; 49():151605. PubMed ID: 32920473
[TBL] [Abstract][Full Text] [Related]
14. p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast.
Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
J Clin Pathol; 2002 Dec; 55(12):936-9. PubMed ID: 12461063
[TBL] [Abstract][Full Text] [Related]
15. Luminal cytokeratin expression profiles of breast papillomas and papillary carcinomas and the utility of a cytokeratin 5/p63/cytokeratin 8/18 antibody cocktail in their distinction.
Reisenbichler ES; Balmer NN; Adams AL; Pfeifer JD; Hameed O
Mod Pathol; 2011 Feb; 24(2):185-93. PubMed ID: 21076459
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
Werling RW; Hwang H; Yaziji H; Gown AM
Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
[TBL] [Abstract][Full Text] [Related]
17. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections.
Moritani S; Kushima R; Sugihara H; Bamba M; Kobayashi TK; Hattori T
Mod Pathol; 2002 Apr; 15(4):397-405. PubMed ID: 11950913
[TBL] [Abstract][Full Text] [Related]
18. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6.
Rabban JT; Koerner FC; Lerwill MF
Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of benign and malignant papillary lesions of the breast.
Papotti M; Eusebi V; Gugliotta P; Bussolati G
Am J Surg Pathol; 1983 Jul; 7(5):451-61. PubMed ID: 6351647
[TBL] [Abstract][Full Text] [Related]
20. CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast.
Tse GM; Tan PH; Ma TK; Gilks CB; Poon CS; Law BK
J Clin Pathol; 2005 Nov; 58(11):1185-8. PubMed ID: 16254109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
